News brief­ing: Gilead, No­vo of­fer first glimpse at NASH cock­tail da­ta; Sean Bo­hen's can­cer biotech sets terms for $170M IPO

Gilead and No­vo Nordisk say their com­bo strat­e­gy for NASH has passed a proof-of-con­cept test, meet­ing the tol­er­a­bil­i­ty end­point across dif­fer­ent com­bi­na­tions while in­duc­ing promis­ing changes in bio­mark­ers.

The Phase II tri­al eval­u­at­ed com­bi­na­tions of No­vo’s semaglu­tide (or Ozem­pic, the GLP-1 re­cep­tor ag­o­nist ap­proved for di­a­betes) and Gilead’s ex­per­i­men­tal FXR ag­o­nist cilofex­or and/or in­ves­ti­ga­tion­al ACC in­hibitor fir­so­co­stat over 24 weeks in 108 pa­tients with non-al­co­holic steato­hep­ati­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER